COVID-19: clinical trials authorized in Spain for active ingredient 2020
As of January 7, 2020, twenty-three clinical trials had been authorized to evaluate the efficacy of hydroxychloroquine as a treatment against coronavirus in Spain. The antivirus drug Remdesivir from the pharmaceutical company Gilead ranked third with a total of nine clinical trials in the country. This medicine has been the first to obtain a conditional authorization from the European Medicines Agency and the American Food and Drug Administration for use in patients with COVID-19.